On July 16, Giant Biogene rose 5.13% in regular trading, trading at HKD 29.8/share, with turnover of HKD 126 million, extending gains from the prior session.
The rally is driven by the rapid commercialization of the company's medical aesthetics product pipeline. Since June, the company's 753 Collagen Needle — China's first recombinant Type I collagen facial injectable — has officially launched. In the same month, the company's self-developed cross-linked recombinant Type III full-length collagen filler received NMPA approval, making it the world's first such product indicated for neck wrinkle improvement.
Huachuang Securities noted that Giant Biogene's medical aesthetics matrix has progressively taken shape, with cosmetics-related reputational risks gradually clearing, signaling an emerging inflection point. CICC maintains an Outperform rating with a target price of HKD 40, while Orient Securities maintains a Buy rating with a target of HKD 43.07, both citing improving fundamentals and the company's expanding multi-category product portfolio spanning Class III devices, Class II devices, and skincare.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments